Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kura Oncology (KURA) EBIT (2024 - 2025)

Kura Oncology (KURA) has disclosed EBIT for 2 consecutive years, with -$80.6 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT fell 379.77% to -$80.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$291.4 million, a 60.42% decrease, with the full-year FY2025 number at -$303.6 million, down 57.16% from a year prior.
  • EBIT was -$80.6 million for Q4 2025 at Kura Oncology, down from -$80.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$16.8 million in Q4 2024 to a low of -$80.6 million in Q4 2025.